Pharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS

NCT06839404 | Recruiting

• 2 other identifiers: PHOEBUS studySRLF 22-033
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

When the flow of blood ejected by the heart drops significantly, that is to say when there is "shock", one of the first treatments undertaken is often volume expansion. This treatment consists of injecting a liquid intravenously, generally in the form of a bolus, that is to say a dose of solute administered all at once, of 250 to 500 mL of fluid over approximately 10 to 30 minutes. The injected fluid expands the blood volume and fills the heart pump, in order to increase the flow it ejects. However, this treatment poses two problems. First, it is only inconsistently effective. It is possible that of the 250-500 mL of fluid administered in the standard way, only a part is effective, whereas, as the effectiveness decreases during the infusion, the rest does not increase cardiac output significantly. However, the average part of the total volume that is ineffective on a large population of patients is not well known. Second, the effects of volume expansion on cardiac output decrease rapidly after the end of administration. However, the average duration of effectiveness of a 250-500 mL fluid bolus, and the factors that influence this duration of effectiveness, are not well determined. The main objective of this research is to measure, among the volume of a fluid bolus, which part does not significantly increase cardiac output. The secondary objective is to measure the average time of effectiveness after the end of the infusion and the factors that influence it.

Conditions

Shock

Outcome Measures

Primary Outcomes (1)

• To measure, during the administration of a fluid bolus in order to perform volume expansion, the volume of fluid which causes an increase in cardiac output of less than 15%.

  We will measure, among the volume administered (500mL), the proportion of infused volume which allowed an increase in cardiac output ≥15% compared to the baseline value. This baseline value will be defined by the average measured over the minute preceding the start of the fluid infusion

  During the fluid bolus administration (<15min)

Secondary Outcomes (4)

• The maximum amplitude of the change induced by volume expansion in cardiac output, mean arterial pressure and central venous pressure

  During the fluid bolus administration (<15min)

• The delay at which this maximum effect appears in terms of cardiac output, mean arterial pressure and central venous pressure

  During the fluid bolus administration (<15min)

• The time following the end of the infusion from which the cardiac output becomes ≤5% of the baseline value

  A period of 120 minutes following the fluid infusion

• The factors that influence these pharmacokinetic variables will be determined

  During the study period (during fluid administration and the period of 120 minutes following the infusion)

Interventions

fluid challenge DRUG

Fluid bolus of 500 mL of crystalloids given at a constant rate between 10 and 15 minutes

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized in intensive care unit and with shock for whom a fluid challenge is administered

You may qualify if:

• Age ≥18 years old
• Hospitalisation in intensive care
• Haemodynamic monitoring already in place with a pulse wave contour analysis-derived estimation of cardiac output (either calibrated or uncalibrated)
• Decision taken by the clinicians in charge of the patient to perform volume expansion by intravenous infusion of a 6 mL/kg crystalloid bolus

You may not qualify if:

• Pregnancy
• Refusal to participate by relatives of the patient or the patient himself
• Other therapeutic modification during volume expansion

Sponsors & Collaborators

• Bicetre Hospital: lead

Study Sites (1)

Bicêtre Hospital

Le Kremlin-Bicêtre, 94320, France

RECRUITING

MeSH Terms

Conditions

Shock

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Xavier Monnet, MD, PhD

CONTACT

+33660862669; xavier.monnet@aphp.fr

Christopher Lai, MD, PhD

CONTACT

+33 (0)145212671; christopher.lai@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: February 17, 2025
• First Posted: February 21, 2025
• Study Start: July 1, 2022
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: February 21, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF, CSR

Locations

FR (1)